← 產業報告目錄
Peptide Therapeutics Contract API Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operation (Preclinical/Clinical And Commercial), Type Of Synthesis Method Used (Non-Chemical Synthesis Method And Chemical Synthesis Method), And Enterprise Type (Large Enterprises And Small And Medium Enterprises), Region And Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-30頁數 165報告編號 INSIGHTACE-8a5651dc05
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
With a 2023 valuation of USD 2.36 billion, the global Peptide Therapeutics Contract API Manufacturing Market is expected to expand to USD 3.77 billion by 2031, demonstrating a CAGR of 6.3% during the 2024–2031 forecast window.
Peptide Therapeutics Contract API Manufacturing encompasses a technique of extending the production of drugs with active pharmaceutical components (apis) or the parts that provide an external entity with the d. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is driven by a convergence of factors: rising awareness among end users, continuous product innovation, and the escalating emphasis on efficiency and sustainability within the healthcare sector.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region expected to deliver the strongest growth trajectory through the forecast period, driven by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Peptide Therapeutics Contract API Manufacturing Market Snapshot
Chapter 4. Global Peptide Therapeutics Contract API Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Peptide Therapeutics Contract API Manufacturing Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Peptide Therapeutics Contract API Manufacturing Industry Trends
Chapter 5. Peptide Therapeutics Contract API Manufacturing Market Segmentation 1: By Scale of Operation, Estimates & Trend Analysis
5.1. Market Share by Scale of Operation, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Scale of Operation:
5.2.1. Preclinical/Clinical
5.2.2. Commercial
Chapter 6. Peptide Therapeutics Contract API Manufacturing Market Segmentation 2: By Type of Synthesis Method Used, Estimates & Trend Analysis
6.1. Market Share by Type of Synthesis Method Used, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of Synthesis Method Used:
6.2.1. Non-chemical Synthesis Method
6.2.2. Chemical Synthesis Method
Chapter 7. Peptide Therapeutics Contract API Manufacturing Market Segmentation 3: By Enterprise Type, Estimates & Trend Analysis
7.1. Market Share by Enterprise Type, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Enterprise Types:
7.2.1. Large Enterprise
7.2.2. Small and Medium Enterprise
Chapter 8. Peptide Therapeutics Contract API Manufacturing Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Peptide Therapeutics Contract API Manufacturing Market, Regional Snapshot 2023 & 2031
8.2. North America
8.2.1. North America Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2019-2031
8.2.3. North America Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Type of Synthesis Method Used, 2019-2031
8.2.4. North America Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Enterprise Type, 2019-2031
8.3. Europe
8.3.1. Europe Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2019-2031
8.3.3. Europe Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Type of Synthesis Method Used, 2019-2031
8.3.4. Europe Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Enterprise Type, 2019-2031
8.4. Asia Pacific
8.4.1. Asia Pacific Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2019-2031
8.4.3. Asia Pacific Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts By Type of Synthesis Method Used, 2019-2031
8.4.4. Asia Pacific Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Enterprise Type, 2019-2031
8.5. Latin America
8.5.1. Latin America Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2019-2031
8.5.3. Latin America Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Type of Synthesis Method Used, 2019-2031
8.5.4. Latin America Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Enterprise Type, 2019-2031
8.6. Middle East & Africa
8.6.1. Middle East & Africa Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2019-2031
8.6.3. Middle East & Africa Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Type of Synthesis Method Used, 2019-2031
8.6.4. Middle East & Africa Peptide Therapeutics Contract API Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Enterprise Type, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Ambiopharm Inc
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service Offerings
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Auspep
9.2.3. Bachem Holding AG
9.2.4. BCN Peptides
9.2.5. Chinese Peptide Company
9.2.6. CordenPharma
9.2.7. CPC Scientific
9.2.8. Creative Peptides
9.2.9. CSBio
9.2.10. Hybio Pharmaceutical
9.2.11. Peptide Institute, Inc.
9.2.12. PolyPeptide Group
9.2.13. ScinoPharm
9.2.14. Senn Chemicals AG
9.2.15. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們